08.01.2024 13:30:00

Tecan to present at upcoming Investor Conferences

Männedorf, Switzerland, January 8, 2024 – The Tecan Group (SIX Swiss Exchange: TECN) today announced that it will attend and present at the following investor conferences this week:

42nd Annual J.P. Morgan Healthcare Conference, San Francisco
Date: 10 January 2024
Presentation: 09:00 am PST (6:00 pm CET)
Presenter: Dr. Achim von Leoprechting, CEO, Tecan
Additional participant: Tania Micki, CFO
Webcast live under the "Investor Relations" tab of Tecan's website www.tecan.com
A replay of the webcast will be available after the presentation and will remain available for 30 days.

Baader Helvea Swiss Equities Conference, Bad Ragaz
Date: 11 January 2024
Participants: Klaus Lun, EVP, Head of the Life Sciences Business division
        Ralf Griebel, EVP, Head of the Partnering Business division
        Martin Brändle, SVP, Corp. Comm. & Investor Relations
Not webcasted        

Octavian Seminar 2024, Davos
Date: 12 January 2024
Participants: Klaus Lun, EVP, Head of the Life Sciences Business division
        Ralf Griebel, EVP, Head of the Partnering Business division
        Martin Brändle, SVP, Corp. Comm. & Investor Relations
Not webcasted        

About Tecan
Tecan (www.tecan.com) improves people’s lives and health by empowering customers to scale healthcare innovation globally from life science to the clinic. Tecan is a pioneer and global leader in laboratory automation. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments, components and medical devices that are then distributed by partner companies. Founded in Switzerland in 1980, the company has more than 3,500 employees, with manufacturing, research and development sites in Europe, North America and Asia, and maintains a sales and service network in over 70 countries. In 2022, Tecan generated sales of CHF 1,144 million (USD 1,192 million; EUR 1,144 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).
         

For further information:

Tecan Group
Martin Braendle
Senior Vice President, Corporate Communications & IR
Tel. +41 (0) 44 922 84 30
Fax +41 (0) 44 922 88 89
investor@tecan.com
www.tecan.com

 

Attachment


Analysen zu Tecan (N)mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Tecan (N) 229,00 13,59% Tecan (N)